NASDAQ:ABUS - Arbutus Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.82 +0.07 (+1.04 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$6.75
Today's Range$6.60 - $6.85
52-Week Range$3.20 - $8.25
Volume318,362 shs
Average Volume176,972 shs
Market Capitalization$350.32 million
P/E Ratio-3.83
Dividend YieldN/A
Beta1.04
Arbutus Biopharma logoArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.

Receive ABUS News and Ratings via Email

Sign-up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200

Debt

Debt-to-Equity Ratio0.01
Current Ratio16.86
Quick Ratio16.86

Price-To-Earnings

Trailing P/E Ratio-3.83
Forward P/E Ratio-4.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.70 million
Price / Sales35.16
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.83

Profitability

EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-705.09%
Return on Equity-61.50%
Return on Assets-36.20%

Miscellaneous

Employees130
Outstanding Shares55,170,000

Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions

What is Arbutus Biopharma's stock symbol?

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma (NASDAQ:ABUS) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. The biopharmaceutical company earned $1.40 million during the quarter. Arbutus Biopharma had a negative return on equity of 61.50% and a negative net margin of 705.09%. View Arbutus Biopharma's Earnings History.

When is Arbutus Biopharma's next earnings date?

Arbutus Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Arbutus Biopharma.

What price target have analysts set for ABUS?

5 Wall Street analysts have issued 1-year price targets for Arbutus Biopharma's stock. Their forecasts range from $5.00 to $13.00. On average, they anticipate Arbutus Biopharma's stock price to reach $8.40 in the next year. View Analyst Ratings for Arbutus Biopharma.

Who are some of Arbutus Biopharma's key competitors?

Who are Arbutus Biopharma's key executives?

Arbutus Biopharma's management team includes the folowing people:
  • Dr. Mark Joseph Murray, Pres, CEO & Director (Age 69)
  • Dr. Peter Lutwyche Ph.D., Chief Technology Officer (Age 52)
  • Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 60)
  • Dr. Elizabeth Howard Ph.D., J.D., Exec. VP & Gen. Counsel (Age 64)
  • Mr. Koert VandenEnden C.A., C.P.A., Interim CFO & VP of Fin. (Age 39)

Has Arbutus Biopharma been receiving favorable news coverage?

News articles about ABUS stock have been trending somewhat negative this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a daily sentiment score of -0.01 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.67 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Foresite Capital Management IV LLC (2.69%), BlackRock Inc. (1.25%), JPMorgan Chase & Co. (0.40%), Victory Capital Management Inc. (0.30%), Eversept Partners LLC (0.21%) and Citadel Advisors LLC (0.12%). View Institutional Ownership Trends for Arbutus Biopharma.

Which institutional investors are selling Arbutus Biopharma stock?

ABUS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Arbutus Biopharma.

Which institutional investors are buying Arbutus Biopharma stock?

ABUS stock was purchased by a variety of institutional investors in the last quarter, including Foresite Capital Management IV LLC, JPMorgan Chase & Co., Citadel Advisors LLC, DekaBank Deutsche Girozentrale, Victory Capital Management Inc. and Eversept Partners LLC. View Insider Buying and Selling for Arbutus Biopharma.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma's stock price today?

One share of ABUS stock can currently be purchased for approximately $6.82.

How big of a company is Arbutus Biopharma?

Arbutus Biopharma has a market capitalization of $350.32 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.

How can I contact Arbutus Biopharma?

Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]


MarketBeat Community Rating for Arbutus Biopharma (ABUS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.